Galmed Pharmaceuticals (GLMD) News Today $1.45 +0.08 (+5.84%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.02 (-1.31%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Galmed Pharmaceuticals (NASDAQ:GLMD) Cut to Sell at Wall Street ZenAugust 3, 2025 | americanbankingnews.comGalmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHMay 27, 2025 | prnewswire.comGALMED PHARMACEUTICALS Earnings Results: $GLMD Reports Quarterly EarningsMay 24, 2025 | nasdaq.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | finanznachrichten.deGalmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finanznachrichten.deGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finance.yahoo.comGalmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’May 7, 2025 | msn.comGalmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly EnhancesMay 6, 2025 | finanznachrichten.deGalmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsMay 6, 2025 | prnewswire.comAnalysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)April 30, 2025 | theglobeandmail.comGalmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual FormulationApril 28, 2025 | prnewswire.comGalmed launches VCU collaboration to tackle drug resistance in GI cancersApril 19, 2025 | markets.businessinsider.comGalmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI CancersApril 17, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 InhibitorApril 15, 2025 | finanznachrichten.deGalmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 InhibitorApril 15, 2025 | prnewswire.comGalmed Reports Positive Part 1 Results From AM-001 Study Of Aramchol Meglumine - Quick FactsApril 12, 2025 | nasdaq.comGalmed’s Aramchol Meglumine shows improved results in Part 1 of AM-001 studyApril 10, 2025 | markets.businessinsider.comGalmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 InhibitorApril 10, 2025 | prnewswire.comMaxim Group Downgrades Galmed Pharmaceuticals (GLMD)April 5, 2025 | msn.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024April 2, 2025 | prnewswire.comGalmed awarded extension of Aramchol patent protection to 2039March 22, 2025 | markets.businessinsider.comGalmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination TherapyMarch 20, 2025 | prnewswire.comGalmed Pharmaceuticals Amends Equity Purchase AgreementOctober 23, 2024 | markets.businessinsider.comGalmed publishes Results from Aramchol Phase 3 Open Label part in HepatologySeptember 25, 2024 | prnewswire.comMarketBeat Week in Review – 9/16 - 9/20 (GLMD)Stocks got a boost as the Federal Reserve cut interest rates, but investors should expect more volatility as economic data continues to deliver mixed signals...September 21, 2024 | marketbeat.comBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About YetSeptember 20, 2024 | benzinga.comGalmed Pharmaceuticals Stock Is Soaring Thursday: Here's WhySeptember 19, 2024 | msn.comGalmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesSeptember 19, 2024 | prnewswire.comGalmed Pharmaceuticals (NASDAQ:GLMD) Stock, Short Interest ReportSeptember 18, 2024 | benzinga.comGalmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing PriceSeptember 18, 2024 | marketwatch.comGalmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short SqueezeSeptember 18, 2024 | msn.comCrude Oil Gains Over 1%; US Business Inventories Increase In JulySeptember 18, 2024 | msn.comGalmed Pharmaceuticals Surges After Regaining Nasdaq ComplianceSeptember 17, 2024 | marketwatch.comGalmed Pharma Surges 400%: What's Behind the Explosion?September 17, 2024 | msn.comGalmed Pharmaceuticals Surges 400%: What's Behind the Explosion?Galmed Pharmaceuticals (NASDAQ: GLMD) stock skyrocketed nearly 400%, trading over 80 million shares, compared to its average of 75,000.September 17, 2024 | marketbeat.comGalmed Pharmaceuticals Ltd.August 25, 2024 | barrons.comGLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024June 22, 2024 | investorplace.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 13, 2024 | fool.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 10, 2024 | investorplace.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023April 4, 2024 | prnewswire.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisMarch 15, 2024 | markets.businessinsider.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisMarch 15, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd (GPH.BE)February 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)January 3, 2024 | uk.finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 20, 2023 | finance.yahoo.comGalmed Pharmaceuticals Ltd GLMDNovember 4, 2023 | morningstar.comMGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisSeptember 26, 2023 | finance.yahoo.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08August 3, 2023 | nasdaq.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | marketwatch.com Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Media Mentions By Week GLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLMD News Sentiment▼-0.810.38▲Average Medical News Sentiment GLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLMD Articles This Week▼10▲GLMD Articles Average Week Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMCC News Today RNAZ News Today ACXP News Today DWTX News Today XFOR News Today APRE News Today SNGX News Today SONN News Today CHRO News Today ADXN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLMD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLMD Stock Alerts